LENZ Therapeutics (LENZ) Stock Forecast, Price Target & Predictions


OverviewFinancialsChartTranscripts

LENZ Stock Forecast


LENZ Therapeutics stock forecast is as follows: an average price target of $34.00 (represents a 4.20% upside from LENZ’s last price of $32.63) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

LENZ Price Target


The average price target for LENZ Therapeutics (LENZ) is $34.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $36.00 to $32.00. This represents a potential 4.20% upside from LENZ's last price of $32.63.

LENZ Analyst Ratings


Buy

According to 4 Wall Street analysts, LENZ Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for LENZ stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

LENZ Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 15, 2024Joseph CatanzaroPiper Sandler$36.00$22.2561.80%10.33%
Aug 15, 2024Yigal NochomovitzCitigroup$32.00$23.5036.17%-1.93%

The latest LENZ Therapeutics stock forecast, released on Aug 15, 2024 by Joseph Catanzaro from Piper Sandler, set a price target of $36.00, which represents a 61.80% increase from the stock price at the time of the forecast ($22.25), and a 10.33% increase from LENZ last price ($32.63).

LENZ Therapeutics Price Target by Period


1M3M12M
# Anlaysts--2
Avg Price Target--$34.00
Last Closing Price$32.63$32.63$32.63
Upside/Downside-100.00%-100.00%4.20%

In the current month, the average price target of LENZ Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to LENZ Therapeutics's last price of $32.63. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Sep 26, 2024Raymond JamesOutperformInitialise
Aug 15, 2024Piper SandlerOverweightOverweightHold
Aug 15, 2024CitigroupBuyBuyHold
Apr 15, 2024William BlairOutperformInitialise
Apr 09, 2024CitigroupBuyInitialise

LENZ Therapeutics's last stock rating was published by Raymond James on Sep 26, 2024. The company Initialise its LENZ rating from "null" to "Outperform".

LENZ Therapeutics Financial Forecast


LENZ Therapeutics Revenue Forecast

Revenue
Avg Forecast
High Forecast
Low Forecast
# Analysts
Surprise %

LENZ Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. LENZ's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

LENZ Therapeutics EBITDA Forecast

# Analysts
EBITDA
Avg Forecast
High Forecast
Low Forecast
Surprise %

undefined analysts predict LENZ's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than LENZ Therapeutics's previous annual EBITDA (undefined) of $NaN.

LENZ Therapeutics Net Income Forecast

# Analysts
Net Income
Avg Forecast
High Forecast
Low Forecast
Surprise %

LENZ Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LENZ's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

LENZ Therapeutics SG&A Forecast

# Analysts
SG&A
Avg Forecast
High Forecast
Low Forecast
Surprise %

LENZ Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to LENZ last annual SG&A of $NaN (undefined).

LENZ Therapeutics EPS Forecast

# Analysts
EPS
Avg Forecast
High Forecast
Low Forecast
Surprise %

According to undefined Wall Street analysts, LENZ Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LENZ previous annual EPS of $NaN (undefined).

LENZ Forecast FAQ


Is LENZ Therapeutics a good buy?

Yes, according to 4 Wall Street analysts, LENZ Therapeutics (LENZ) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of LENZ's total ratings.

What is LENZ's price target?

LENZ Therapeutics (LENZ) average price target is $34 with a range of $32 to $36, implying a 4.20% from its last price of $32.63. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will LENZ Therapeutics stock go up soon?

According to Wall Street analysts' prediction for LENZ stock, the company can go up by 4.20% (from the last price of $32.63 to the average price target of $34), up by 10.33% based on the highest stock price target, and down by -1.93% based on the lowest stock price target.

Can LENZ Therapeutics stock reach $50?

LENZ's average twelve months analyst stock price target of $34 does not support the claim that LENZ Therapeutics can reach $50 in the near future.